Febrile Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major febrile neutropenia markets reached a value of US$ 10.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 16.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.15% during 2024-2034.
The febrile neutropenia market has been comprehensively analyzed in IMARC's new report titled "Febrile Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Febrile neutropenia is a medical condition characterized by the presence of a fever (body temperature above 38.3°C or 101°F) in a patient with low neutrophil counts. This disease can affect the body's ability to fight infections, increasing the likelihood of health complications, such as severe sepsis and septic shock. The common indications of the ailment include unexplained fever, general weakness, tiredness, episodes of chills and sweating, increased heart rate, sore throat, difficulty swallowing, painful mouth sores, coughing, shortness of breath, chest and abdominal pain, nausea, vomiting, diarrhea, etc. The diagnosis of febrile neutropenia is mainly based on the patient's symptoms, medical history, and physical examination findings. Blood cultures and a complete blood count test are also utilized to detect the presence of bacteria or fungi in the bloodstream and identify other abnormalities. The healthcare provider may further perform numerous imaging studies, such as a chest X-ray, a computed tomography (CT) scan, an ultrasound, etc., to identify the source of infection and rule out other possible causes of indications among patients.
The increasing utilization of chemotherapy or radiation therapy, which can suppress the bone marrow's ability to produce new blood cells, is primarily driving the febrile neutropenia market. In addition to this, the rising incidences of various associated risk factors, including nutritional deficiencies, kidney diseases, usage of certain medications, like corticosteroids, that can affect immune function, etc., are also bolstering the market growth. Furthermore, the inflating adoption of broad-spectrum antibiotics to control the infection while providing coverage against a wide array of other potential pathogens is creating a positive outlook for the market. Besides this, the escalating application of colony-stimulating factors, such as filgrastim and pegfilgrastim, to treat the underlying symptoms of the ailment is also propelling the market growth. These medications work by stimulating the production of white blood cells, specifically neutrophils, to accelerate the recovery of the immune system. Additionally, the emerging popularity of intravenous antifungal therapy for treating the condition in patients who are unresponsive to other conventional antibiotic regimens is expected to drive the febrile neutropenia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the febrile neutropenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for febrile neutropenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the febrile neutropenia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the febrile neutropenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the febrile neutropenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current febrile neutropenia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the febrile neutropenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the febrile neutropenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the febrile neutropenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of febrile neutropenia across the seven major markets?
What is the number of prevalent cases (2018-2034) of febrile neutropenia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of febrile neutropenia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with febrile neutropenia across the seven major markets?
What is the size of the febrile neutropenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of febrile neutropenia?
What will be the growth rate of patients across the seven major markets?
Febrile Neutropenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for febrile neutropenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the febrile neutropenia market?
What are the key regulatory events related to the febrile neutropenia market?
What is the structure of clinical trial landscape by status related to the febrile neutropenia market?
What is the structure of clinical trial landscape by phase related to the febrile neutropenia market?
What is the structure of clinical trial landscape by route of administration related to the febrile neutropenia market?
The febrile neutropenia market has been comprehensively analyzed in IMARC's new report titled "Febrile Neutropenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Febrile neutropenia is a medical condition characterized by the presence of a fever (body temperature above 38.3°C or 101°F) in a patient with low neutrophil counts. This disease can affect the body's ability to fight infections, increasing the likelihood of health complications, such as severe sepsis and septic shock. The common indications of the ailment include unexplained fever, general weakness, tiredness, episodes of chills and sweating, increased heart rate, sore throat, difficulty swallowing, painful mouth sores, coughing, shortness of breath, chest and abdominal pain, nausea, vomiting, diarrhea, etc. The diagnosis of febrile neutropenia is mainly based on the patient's symptoms, medical history, and physical examination findings. Blood cultures and a complete blood count test are also utilized to detect the presence of bacteria or fungi in the bloodstream and identify other abnormalities. The healthcare provider may further perform numerous imaging studies, such as a chest X-ray, a computed tomography (CT) scan, an ultrasound, etc., to identify the source of infection and rule out other possible causes of indications among patients.
The increasing utilization of chemotherapy or radiation therapy, which can suppress the bone marrow's ability to produce new blood cells, is primarily driving the febrile neutropenia market. In addition to this, the rising incidences of various associated risk factors, including nutritional deficiencies, kidney diseases, usage of certain medications, like corticosteroids, that can affect immune function, etc., are also bolstering the market growth. Furthermore, the inflating adoption of broad-spectrum antibiotics to control the infection while providing coverage against a wide array of other potential pathogens is creating a positive outlook for the market. Besides this, the escalating application of colony-stimulating factors, such as filgrastim and pegfilgrastim, to treat the underlying symptoms of the ailment is also propelling the market growth. These medications work by stimulating the production of white blood cells, specifically neutrophils, to accelerate the recovery of the immune system. Additionally, the emerging popularity of intravenous antifungal therapy for treating the condition in patients who are unresponsive to other conventional antibiotic regimens is expected to drive the febrile neutropenia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the febrile neutropenia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for febrile neutropenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the febrile neutropenia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the febrile neutropenia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the febrile neutropenia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current febrile neutropenia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the febrile neutropenia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the febrile neutropenia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the febrile neutropenia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of febrile neutropenia across the seven major markets?
What is the number of prevalent cases (2018-2034) of febrile neutropenia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of febrile neutropenia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with febrile neutropenia across the seven major markets?
What is the size of the febrile neutropenia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of febrile neutropenia?
What will be the growth rate of patients across the seven major markets?
Febrile Neutropenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for febrile neutropenia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the febrile neutropenia market?
What are the key regulatory events related to the febrile neutropenia market?
What is the structure of clinical trial landscape by status related to the febrile neutropenia market?
What is the structure of clinical trial landscape by phase related to the febrile neutropenia market?
What is the structure of clinical trial landscape by route of administration related to the febrile neutropenia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FEBRILE NEUTROPENIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FEBRILE NEUTROPENIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FEBRILE NEUTROPENIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 FEBRILE NEUTROPENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FEBRILE NEUTROPENIA - UNMET NEEDS
10 FEBRILE NEUTROPENIA - KEY ENDPOINTS OF TREATMENT
11 FEBRILE NEUTROPENIA - MARKETED PRODUCTS
11.1 List of Febrile Neutropenia Marketed Drugs Across the Top 7 Markets
11.1.1 Neupogen (Filgrastim) - Amgen/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rolvedon (Eflapegrastim) - Hanmi Pharmaceutical/Spectrum Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Neulasta (Pegfilgrastim) - Amgen/Kyowa Kirin
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Maxipime (Cefepime) - Bristol-Myers Squibb
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 AmBisome (Amphotericin B liposomal) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 FEBRILE NEUTROPENIA - PIPELINE DRUGS
12.1 List of Febrile Neutropenia Pipeline Drugs Across the Top 7 Markets
12.1.1 MD 110 - Mochida Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. FEBRILE NEUTROPENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FEBRILE NEUTROPENIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FEBRILE NEUTROPENIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Febrile Neutropenia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Febrile Neutropenia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Febrile Neutropenia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Febrile Neutropenia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Febrile Neutropenia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Febrile Neutropenia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Febrile Neutropenia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Febrile Neutropenia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Febrile Neutropenia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Febrile Neutropenia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Febrile Neutropenia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Febrile Neutropenia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Febrile Neutropenia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Febrile Neutropenia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Febrile Neutropenia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Febrile Neutropenia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Febrile Neutropenia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Febrile Neutropenia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Febrile Neutropenia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Febrile Neutropenia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Febrile Neutropenia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Febrile Neutropenia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Febrile Neutropenia - Access and Reimbursement Overview
16 FEBRILE NEUTROPENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FEBRILE NEUTROPENIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FEBRILE NEUTROPENIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FEBRILE NEUTROPENIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FEBRILE NEUTROPENIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FEBRILE NEUTROPENIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 FEBRILE NEUTROPENIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FEBRILE NEUTROPENIA - UNMET NEEDS
10 FEBRILE NEUTROPENIA - KEY ENDPOINTS OF TREATMENT
11 FEBRILE NEUTROPENIA - MARKETED PRODUCTS
11.1 List of Febrile Neutropenia Marketed Drugs Across the Top 7 Markets
11.1.1 Neupogen (Filgrastim) - Amgen/Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rolvedon (Eflapegrastim) - Hanmi Pharmaceutical/Spectrum Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Neulasta (Pegfilgrastim) - Amgen/Kyowa Kirin
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Maxipime (Cefepime) - Bristol-Myers Squibb
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 AmBisome (Amphotericin B liposomal) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 FEBRILE NEUTROPENIA - PIPELINE DRUGS
12.1 List of Febrile Neutropenia Pipeline Drugs Across the Top 7 Markets
12.1.1 MD 110 - Mochida Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. FEBRILE NEUTROPENIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FEBRILE NEUTROPENIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FEBRILE NEUTROPENIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Febrile Neutropenia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Febrile Neutropenia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Febrile Neutropenia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Febrile Neutropenia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Febrile Neutropenia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Febrile Neutropenia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Febrile Neutropenia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Febrile Neutropenia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Febrile Neutropenia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Febrile Neutropenia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Febrile Neutropenia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Febrile Neutropenia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Febrile Neutropenia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Febrile Neutropenia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Febrile Neutropenia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Febrile Neutropenia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Febrile Neutropenia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Febrile Neutropenia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Febrile Neutropenia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Febrile Neutropenia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Febrile Neutropenia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Febrile Neutropenia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Febrile Neutropenia - Access and Reimbursement Overview
16 FEBRILE NEUTROPENIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FEBRILE NEUTROPENIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FEBRILE NEUTROPENIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
